find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Phase 1 Clinical Trials
Phase I
Accepting Patients
nct/study# NCT04543188 / C4471001
A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety And Efficacy Of Pf-07284890 (Arry-461) In Participants With Braf V600-Mutant Solid Tumors With And Without Brain Involvement
Learn More
Phase 1 Clinical Trials
Phase I
Accepting Patients
nct/study# NCT04881045 / C4401001
(CD47 And PD-L1) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS FQ Completed On: 2/4/2021
Learn More
Phase 1 Clinical Trials
Phase I
Accepting Patients
nct/study# NCT04458259 / C4201002
A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety And Tolerability Study Of Pf-07265807 In Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT04408599 / NC410-01
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC410 In Subjects With Advanced Or Metastatic Solid Tumors
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT03665285 / NC318-01
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC318 In Subjects With Advanced Or Metastatic Solid Tumors
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT04849273 / TPX-0131-01
A Phase 1/2 Study Of Tpx-0131, A Novel Oral Alk Tyrosine Kinase Inhibitor In Subjects With Alk+ Advanced Or Metastatic Nsclc
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.